Veridex, a Johnson & Johnson company, has introduced CELLTRACKS Circulating Melanoma Cell (CMC) kit, which allows research scientists to capture CMCs for research studies.
Using proprietary immunomagnetic technology to capture and count CMCs, the CELLTRACKS CMC kit is designed to offer data that support researchers engineering investigational therapies that are based on a specific protein or mutation.
The CELLTRACKS CMC kit is an enabling technology for using biomarkers to identify and enumerate CMCs, melanoma cells that have detached from tumors and entered the blood stream.
Based on the same immunomagnetic technology that powers Veridex’s CELLSEARCH technology, researchers can use the kit to capture CMCs and then select a protein biomarker of their choosing to further refine their research.
Veridex Cellular Research & Development director Mark Connelly said current methods of melanoma cell capture, such as biopsy and polymerase chain reaction, are time intensive and the new kit will automate the process, making it simple and reproducible.